Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4
Abstract
Hereditary cancers derive from gene defects that often compromise DNA repair. Thus, BRCA-associated cancers are sensitive to DNA-damaging agents such as cisplatin. The efficacy of cisplatin is limited, however, by the development of resistance. One cisplatin resistance mechanism is restoration of homologous recombination (HR), which can result from BRCA reversion mutations. However, in BRCA2 mutant cancers, cisplatin resistance can occur independently of restored HR by a mechanism that remains unknown. Here we performed a genome-wide shRNA screen and found that loss of the nucleosome remodeling factor CHD4 confers cisplatin resistance. Restoration of cisplatin resistance is independent of HR but correlates with restored cell cycle progression, reduced chromosomal aberrations, and enhanced DNA damage tolerance. Suggesting clinical relevance, cisplatin-resistant clones lacking genetic reversion of BRCA2 show de novo loss of CHD4 expression in vitro. Moreover, BRCA2 mutant ovarian cancers with reduced CHD4 expression significantly correlate with shorter progression-free survival and shorter overall survival. Collectively, our findings indicate that CHD4 modulates therapeutic response in BRCA2 mutant cancer cells.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 01, 2015
- Source ID
- 10.1101/gad.256214.114
Entities
People
- Janelle A. Hayes
- Michael R Green
- Min Peng
- Panagiotis A Konstantinopoulos
- Ryan W. Serra
- Sharon Cantor
- Shawna Guillemette
Organizations
- National Institutes of Health
- United States Department of Defense